<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2436">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01545843</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH077690</org_study_id>
    <nct_id>NCT01545843</nct_id>
  </id_info>
  <brief_title>Repeated Partial Sleep Deprivation to Augment SSRI Response in Depression</brief_title>
  <official_title>Repeated Partial Sleep Deprivation to Augment SSRI Response in Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether changing sleep patterns improves response
      to an antidepressant medication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Depression is common and associated with social and economic costs. Although antidepressant
      medications are an effective treatment for depression, it can take as long as 6-8 weeks
      before symptoms improve, and 20-35% of individuals who use antidepressants still experience
      depression symptoms.

      New treatments that accelerate response to antidepressants are important to reduce the
      burden of depression. The objectives of the proposed study are (1) to evaluate the effects
      of partial sleep deprivation compared to no sleep deprivation for improving response to 8
      weeks of fluoxetine 20-40 mg treatment and (2) to examine the underlying sleep mechanisms of
      treatment response.

      Participants who are eligible for the study will be randomly assigned to one of three sleep
      schedules for a 2-week period while taking fluoxetine: no sleep deprivation (8 hours time in
      bed), late bedtime (6 hours time in bed, with 2 hour bedtime delay) or early risetime (6
      hours time in bed, with 2 hour advancement of rise time). Participants will spend a total of
      7 nights in our sleep laboratory and will be followed on fluoxetine for an 8-week period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Hamilton Rating Scale for Depression-17 Item Minus Sleep Items</measure>
    <time_frame>Post-treatment (8 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total score on a clinician-rated measure of depressive symptoms, minus 3 sleep items Total score range: 0-46. Higher scores represent more severe depression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depressive Symptoms (QIDS)</measure>
    <time_frame>Post-treatment (8 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patient-reported depression symptom severity at post-treatment, total score. Total scores range from 0 to 27. Higher scores represent more severe depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh Sleep Quality Index</measure>
    <time_frame>Posttreatment (8 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Self-report measure of sleep quality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EEG Sleep Measures</measure>
    <time_frame>Baseline, 2 weeks, 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of EEG activity during sleep using polysomnography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Neuropsychological Functioning</measure>
    <time_frame>Baseline, 2 weeks, 8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Change in multiple domains of neuropsychological functioning (e.g., memory, attention, executive functioning)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>No sleep deprivation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sleep scheduling plus fluoxetine. 8 hours time in bed for two weeks plus fluoxetine for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late bedtime sleep deprivation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sleep scheduling plus fluoxetine. 6 hours time in bed for two weeks plus fluoxetine for 8 weeks. Bedtime delayed by 2 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Early risetime sleep deprivation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sleep scheduling plus fluoxetine. 6 hours time in bed for two weeks plus fluoxetine for 8 weeks. Risetime advanced by 2 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Sleep scheduling</intervention_name>
    <description>8 hours vs. 6 hours time in bed for two weeks, with either 2 hour advance of risetime, or 2 hour delay of bedtime</description>
    <arm_group_label>No sleep deprivation</arm_group_label>
    <arm_group_label>Late bedtime sleep deprivation</arm_group_label>
    <arm_group_label>Early risetime sleep deprivation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine</intervention_name>
    <description>20-40 mg fluoxetine daily for 8 weeks</description>
    <arm_group_label>No sleep deprivation</arm_group_label>
    <arm_group_label>Late bedtime sleep deprivation</arm_group_label>
    <arm_group_label>Early risetime sleep deprivation</arm_group_label>
    <other_name>Prozac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 18 and 65 years old

          -  Current major depressive episode

          -  Habitual TIB of 7 to &lt; 10 hours

          -  No antidepressant medications for â‰¥ 2 weeks (4 weeks for MAOIs or longer acting
             antidepressants)

          -  Score of at least 18 on the Hamilton Rating Scale of Depression

        Exclusion Criteria:

          -  Alcohol or substance abuse/dependence in past 6 months

          -  Current posttraumatic stress disorder or bulimia nervosa (past 6 months)

          -  Lifetime history of bipolar I or II disorder, schizophrenia/other psychotic disorder,
             and anorexia nervosa

          -  Trials of fluoxetine in the past 6 months

          -  Medical disorders or pain syndromes that may affect sleep or are associated with
             significant depression (e.g. thyroid or Cushing's disease); history of head trauma
             with loss of consciousness of &gt; 5 minutes; history of seizures

          -  Sleep disorders other than insomnia, such as sleep apnea and periodic limb movement
             disorder

          -  Current use of prescription, over-the-counter, or naturopathic remedies for sleep
             (e.g., barbiturates, benzodiazepine agonists, nonbenzodiazepine hypnotics,
             analgesics) or depression (e.g., Sam-E, St. John's Wort)

          -  Currently working evening or midnight shift (subjects who have recently traveled
             across multiple time zones will be included at the discretion of the PI).

          -  Currently at risk for drowsy driving or employment that requires routine operation of
             transportation vehicles (e.g., truck/taxi driver, airline pilot) or hazardous
             equipment.

          -  Known allergy, hypersensitivity or contraindication to study medication

          -  Females: pregnant or nursing
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Todd Arnedt, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <lastchanged_date>January 19, 2015</lastchanged_date>
  <firstreceived_date>January 12, 2012</firstreceived_date>
  <firstreceived_results_date>January 13, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>J. Todd Arnedt</investigator_full_name>
    <investigator_title>Assistant Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>depression</keyword>
  <keyword>sleep</keyword>
  <keyword>treatment</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Sleep Deprivation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluoxetine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>No Sleep Deprivation</title>
          <description>8 hours time in bed for two weeks plus fluoxetine for 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>Late Bedtime Sleep Deprivation</title>
          <description>6 hours time in bed for two weeks plus fluoxetine for 8 weeks. Bedtime delayed by 2 hours.</description>
        </group>
        <group group_id="P3">
          <title>Early Risetime Sleep Deprivation</title>
          <description>6 hours time in bed for two weeks plus fluoxetine for 8 weeks. Bedtime delayed by 2 hours.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>No Sleep Deprivation</title>
          <description>8 hours time in bed plus medication
Sleep scheduling: 8 hours time in bed for two weeks
Fluoxetine: 20-40 mg fluoxetine daily for 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>Late Bedtime Sleep Deprivation</title>
          <description>6 hours time in bed plus medication
Sleep scheduling:6 hours time in bed for two weeks; bedtime delayed by 2 hours
Fluoxetine: 20-40 mg fluoxetine daily for 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Early Risetime Sleep Deprivation</title>
          <description>6 hours time in bed plus medication
Sleep scheduling:6 hours time in bed for two weeks; risetime advanced by 2 hours
Fluoxetine: 20-40 mg fluoxetine daily for 8 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="24"/>
                <measurement group_id="B3" value="25"/>
                <measurement group_id="B4" value="68"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="26.4" spread="7.4"/>
                <measurement group_id="B2" value="24.4" spread="5.6"/>
                <measurement group_id="B3" value="25.7" spread="7.0"/>
                <measurement group_id="B4" value="25.4" spread="6.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="13"/>
                <measurement group_id="B3" value="14"/>
                <measurement group_id="B4" value="34"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="11"/>
                <measurement group_id="B4" value="34"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hamilton Rating Scale for Depression-17 Item Minus Sleep Items</title>
        <description>Total score on a clinician-rated measure of depressive symptoms, minus 3 sleep items Total score range: 0-46. Higher scores represent more severe depression.</description>
        <time_frame>Post-treatment (8 weeks)</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>No Sleep Deprivation</title>
            <description>8 hours time in bed plus medication
Sleep scheduling: 8 hours time in bed for 2 weeks
Fluoxetine: 20-40 mg fluoxetine daily for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Late Bedtime Sleep Deprivation</title>
            <description>6 hours time in bed plus medication
Sleep scheduling: 6 hours time in bed for two weeks, with 2 hour delay in bedtime
Fluoxetine: 20-40 mg fluoxetine daily for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Early Risetime Sleep Deprivation</title>
            <description>6 hours time in bed plus medication
Sleep scheduling: 6 hours time in bed for two weeks, with 2 hour advance in risetime
Fluoxetine: 20-40 mg fluoxetine daily for 8 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="24"/>
                  <measurement group_id="O3" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Hamilton Rating Scale for Depression-17 Item Minus Sleep Items</title>
            <description>Total score on a clinician-rated measure of depressive symptoms, minus 3 sleep items Total score range: 0-46. Higher scores represent more severe depression.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6.1" spread="6.7"/>
                  <measurement group_id="O2" value="8.1" spread="4.4"/>
                  <measurement group_id="O3" value="6.3" spread="4.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>.202</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quick Inventory of Depressive Symptoms (QIDS)</title>
        <description>Patient-reported depression symptom severity at post-treatment, total score. Total scores range from 0 to 27. Higher scores represent more severe depression.</description>
        <time_frame>Post-treatment (8 weeks)</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>No Sleep Deprivation</title>
            <description>8 hours time in bed plus medication
Sleep scheduling: 8 hours vs. 6 hours time in bed for two weeks
Fluoxetine: 20-40 mg fluoxetine daily for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Late Bedtime Sleep Deprivation</title>
            <description>6 hours time in bed plus medication
Sleep scheduling: 6 hours time in bed for two weeks, with 2 hour delay of bedtime
Fluoxetine: 20-40 mg fluoxetine daily for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Early Risetime Sleep Deprivation</title>
            <description>6 hours time in bed plus medication
Sleep scheduling: 6 hours time in bed for two weeks, with 2 hour advance of risetime
Fluoxetine: 20-40 mg fluoxetine daily for 8 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="24"/>
                  <measurement group_id="O3" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Quick Inventory of Depressive Symptoms (QIDS)</title>
            <description>Patient-reported depression symptom severity at post-treatment, total score. Total scores range from 0 to 27. Higher scores represent more severe depression.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5.3" spread="4.7"/>
                  <measurement group_id="O2" value="6.9" spread="3.3"/>
                  <measurement group_id="O3" value="6.7" spread="4.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pittsburgh Sleep Quality Index</title>
        <description>Self-report measure of sleep quality</description>
        <time_frame>Posttreatment (8 weeks)</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in EEG Sleep Measures</title>
        <description>Measurement of EEG activity during sleep using polysomnography</description>
        <time_frame>Baseline, 2 weeks, 8 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Neuropsychological Functioning</title>
        <description>Change in multiple domains of neuropsychological functioning (e.g., memory, attention, executive functioning)</description>
        <time_frame>Baseline, 2 weeks, 8 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events judged to be related to the study and of moderate or greater severity</desc>
      <group_list>
        <group group_id="E1">
          <title>No Sleep Deprivation</title>
          <description>8 hours time in bed plus medication
Sleep scheduling: 8 hours time in bed for two weeks
Fluoxetine: 20-40 mg fluoxetine daily for 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Late Bedtime Sleep Deprivation</title>
          <description>6 hours time in bed plus medication
Sleep scheduling: 6 hours time in bed for two weeks, two hour delay of bedtime
Fluoxetine: 20-40 mg fluoxetine daily for 8 weeks</description>
        </group>
        <group group_id="E3">
          <title>Early Risetime Sleep Deprivation</title>
          <description>6 hours time in bed plus medication
Sleep scheduling: 6 hours time in bed for two weeks, two hour advance of risetime
Fluoxetine: 20-40 mg fluoxetine daily for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Medication side effects</sub_title>
                <description>Medication side effects judged to be moderately severe</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood worsening</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Sample is largely young, healthy adults</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. J. Todd Arnedt</name_or_title>
      <organization>University of Michigan</organization>
      <phone>734-764-1234</phone>
      <email>tarnedt@med.umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
